Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) EBIAT (2016 - 2025)

Historic EBIAT for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $153.7 million.

  • Neurocrine Biosciences' EBIAT rose 4907.86% to $153.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $478.6 million, marking a year-over-year increase of 4022.85%. This contributed to the annual value of $478.6 million for FY2025, which is 4022.85% up from last year.
  • Neurocrine Biosciences' EBIAT amounted to $153.7 million in Q4 2025, which was up 4907.86% from $209.5 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' EBIAT peaked at $209.5 million during Q3 2025, and registered a low of -$76.6 million during Q1 2023.
  • For the 4-year period, Neurocrine Biosciences' EBIAT averaged around $77.8 million, with its median value being $83.1 million (2023).
  • As far as peak fluctuations go, Neurocrine Biosciences' EBIAT skyrocketed by 15665.8% in 2024, and later plummeted by 8179.72% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' EBIAT (Quarter) stood at $22.5 million in 2021, then soared by 556.44% to $147.7 million in 2023, then crashed by 30.2% to $103.1 million in 2024, then surged by 49.08% to $153.7 million in 2025.
  • Its EBIAT was $153.7 million in Q4 2025, compared to $209.5 million in Q3 2025 and $107.5 million in Q2 2025.